Stephan Schilling

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2506396/publications.pdf

Version: 2024-02-01

34	2,052	430754	477173
papers	citations	18 h-index	29 g-index

34	34	34	1834
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD Mice. Biomolecules, 2022, 12, 399.	1.8	1
2	Natural Products from Plants and Algae for Treatment of Alzheimerâ€™s Disease: A Review. Biomolecules, 2022, 12, 694.	1.8	12
3	Structure and Dynamics of Meprin Î² in Complex with a Hydroxamate-Based Inhibitor. International Journal of Molecular Sciences, 2021, 22, 5651.	1.8	7
4	A glutaminyl cyclase-catalyzed Î±-synuclein modification identified in human synucleinopathies. Acta Neuropathologica, 2021, 142, 399-421.	3.9	13
5	Focused ultrasound with anti-pGlu3 AÎ² enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. Journal of Controlled Release, 2021, 336, 443-456.	4.8	21
6	Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain AÎ² Pathology in Transgenic Mice. International Journal of Molecular Sciences, 2021, 22, 11791.	1.8	10
7	Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimerâ€™s Disease. Biochemistry, 2020, 59, 2585-2591.	1.2	11
8	Development of the clinical candidate PBD-C06, a humanized pGlu3-AÎ²-specific antibody against Alzheimerâ€™s disease with reduced complement activation. Scientific Reports, 2020, 10, 3294.	1.6	17
9	P1â€099: COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATEâ€AÎ² SPECIFIC ANTIBODY (PBDâ€M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASEâ€LIKE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P309.	0.4	0
10	P2â€056: TARGETING ISOASPARTATEâ€MODIFIED AÎ²: A DIFFERENTIAL APPROACH OF PASSIVE IMMUNOTHERAPY. Alzheimer's and Dementia, 2018, 14, P687.	0.4	0
11	Passive AÎ² Immunotherapy: Current Achievements and Future Perspectives. Molecules, 2018, 23, 1068.	1.7	41
12	Continuous assays for meprin alpha and beta using prolyl tripeptidyl aminopeptidase (PtP) from Porphyromonas gingivalis. Analytical Biochemistry, 2018, 559, 11-16.	1.1	7
13	Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimerâ€™s Diseaseâ€"Studies on Relation to Effective Target Occupancy. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 119-130.	1.3	50
14	First insight into structure-activity relationships of selective meprin Î² inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2428-2431.	1.0	20
15	[P4â€“457]: Nâ€TRUNCATED AND PYROGLUTAMATEâ€MODIFIED AÎ² ACCELERATES AGGREGATION OF Î±â€SYNUCLEIN IN VITRO. Alzheimer's and Dementia, 2017, 13, P1505.	0.4	0
16	P4â€298: Meprin Î² is Associated with Formation of Pyroglutamateâ€Modified AÎ² Peptides. Alzheimer's and Dementia, 2016, 12, P1147.	0.4	0
17	IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes. Biological Chemistry, 2016, 397, 45-55.	1.2	23
18	Phosphate ions and glutaminyl cyclases catalyze the cyclization of glutaminyl residues by facilitating synchronized proton transfers. Bioorganic Chemistry, 2015, 60, 98-101.	2.0	13

#	Article	IF	Citations
19	An anti-pyroglutamate-3 AÎ² vaccine reduces plaques and improves cognition in APPswe/PS1Î”E9 mice. Neurobiology of Aging, 2015, 36, 3187-3199.	1.5	45
20	Glutaminyl Cyclase in Human Cortex: Correlation with (pGlu)-Amyloid-Î² Load and Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 385-400.	1.2	90
21	P1-077: EVIDENCE FOR INVOLVEMENT OF MEPRIN B IN FORMATION OF N-TRUNCATED AND PYROGLUTAMATE -MODIFIED (PGLU) ABETA. , 2014, 10, P331-P331.		0
22	Pyroglutamate-3 Amyloid-Î² Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Diseaseâ€“Like Transgenic Mouse Models. American Journal of Pathology, 2013, 183, 369-381.	1.9	102
23	Passive Immunization against Pyroglutamate-3 Amyloid-Î² Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. Neurodegenerative Diseases, 2012, 10, 265-270.	0.8	63
24	Nâ€Terminal pyroglutamate formation of AÎ²38 and AÎ²40 enforces oligomer formation and potency to disrupt hippocampal longâ€term potentiation. Journal of Neurochemistry, 2012, 121, 774-784.	2.1	76
25	Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-Î². Nature, 2012, 485, 651-655.	13.7	369
26	Glutaminyl Cyclases Display Significant Catalytic Proficiency for Glutamyl Substrates. Biochemistry, 2009, 48, 11831-11833.	1.2	38
27	Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides. Biochemistry, 2009, 48, 7072-7078.	1.2	171
28	Glutaminyl cyclase inhibition attenuates pyroglutamate AÎ² and Alzheimer's diseaseâ€“like pathology. Nature Medicine, 2008, 14, 1106-1111.	15.2	316
29	Isolation and Characterization of Glutaminyl Cyclases from Drosophila:â€‰ Evidence for Enzyme Forms with Different Subcellular Localization. Biochemistry, 2007, 46, 10921-10930.	1.2	22
30	On the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro). Biochemistry, 2006, 45, 12393-12399.	1.2	238
31	Continuous assays of glutaminyl cyclase: from development to application. Spectroscopy, 2004, 18, 363-373.	0.8	4
32	Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Letters, 2004, 563, 191-196.	1.3	155
33	Substrate Specificity of Glutaminyl Cyclases from Plants and Animals. Biological Chemistry, 2003, 384, 1583-92.	1.2	59
34	Heterologous Expression and Characterization of Human Glutaminyl Cyclase:Â Evidence for a Disulfide Bond with Importance for Catalytic Activity. Biochemistry, 2002, 41, 10849-10857.	1.2	58